Channeling Stocks

[sludgehound]

nah on links because...

Sorry billy, so busy plus some of the links have my info
embedded in the URLs esp RT ones.

IVOC DC debate is out in public stories.
ADSX one
http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=5745998&src=eDialog/GetCont...

ICGE ANCC dropping.

VRA 10:11 AM


News for 'VRA' - (Viragen Reports on Plans to Produce Multiferon(TM) at New Swedish Manufacturing Facility)


PLANTATION, Fla., Jul 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- Viragen
(Amex: VRA) (OTC Bulletin Board: VGNI) today confirmed that its Swedish
manufacturing facility in Ersboda is on schedule to commence with the production
of Multiferon(TM) in September. The Company has been upgrading and expanding its
production capabilities as a result of a more aggressive business direction for
its natural human alpha interferon drug. The Company previously reported that it
expects to report data later this year from studies evaluating Multiferon for
the treatment of malignant melanoma.

"The combined manufacturing capabilities of our existing facility in Umea with
our new facility in Ersboda will provide us with the compliance and capacity
necessary to focus on our goal to make Multiferon the world's most prescribed
natural human alpha interferon," stated Viragen's CEO Mr. Charles A. Rice.
Construction of the Ersboda facility was completed earlier this year and is
currently undergoing validation required by the Swedish regulatory authorities.

Mr. Rice added, "I plan to personally observe the resumption of production
activities in Sweden in September. With our current inventory of frozen
Multiferon, which has a longer expiry date than finished product, we are well
positioned to support our ongoing business as well as pending new activities."

About Viragen, Inc.:

Viragen is a biotechnology company specializing in the research, development and
commercialization of natural and recombinant protein-based drugs designed to
treat a broad range of viral and malignant diseases. These protein-based drugs
include natural human alpha interferon, monoclonal antibodies and a peptide
drug. Viragen's strategy also includes the development of Avian Transgenic
Technology as a biomanufacturing platform for the large-scale, cost-effective
production of therapeutic proteins.

Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's
majority owned subsidiary, Viragen International, Inc., is publicly traded on
the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners and licensors
include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, Cancer
Research UK, University of Nottingham (U.K.), University of Miami, America's
Blood Centers and the German Red Cross.